Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000068.xml
Download PDF
Semin intervent Radiol 2019; 36(04): 287-297
DOI: 10.1055/s-0039-1698755
DOI: 10.1055/s-0039-1698755
Review Article
Individualized Ablation of Hepatocellular Carcinoma: Tailored Approaches across the Phenotype Spectrum
Further Information
Publication History
Publication Date:
31 October 2019 (online)
Abstract
Ablation is now recommended by international guidelines for the definitive treatment of hepatocellular carcinoma (HCC). Extensive clinical studies have demonstrated outcomes comparable to surgical resection with shorter hospital stays, decreased costs, and improved quality of life. Successful ablation requires complete treatment of both tumor and margin while preserving critical adjacent structures. HCC exhibits highly variable presentations in both anatomic involvement and biology which have significant implications on choice of ablative therapy. There are now abundant ablation modalities and adjunctive techniques which can be used to individualize ablation and maximize curative results. This article provides a patient-centered summary of approaches to HCC ablation in the context of patient performance, hepatic reserve, tumor phenotype and biology, intra- and extrahepatic anatomy, and ablation technology.
-
References
- 1 Marrero JA, Kulik LM, Sirlin CB. , et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2018; 68 (02) 723-750
- 2 Galle PR, Forner A, Llovet JM. , et al; European Association for the Study of the Liver. Electronic Address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 2018; 69 (01) 182-236
- 3 Llovet JM, Fuster J, Bruix J. ; Barcelona-Clínic Liver Cancer Group. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004; 10 (02) (Suppl. 01) S115-S120
- 4 Feng K, Yan J, Li X. , et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol 2012; 57 (04) 794-802
- 5 Chen MS, Li JQ, Zheng Y. , et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006; 243 (03) 321-328
- 6 Uhlig J, Sellers CM, Stein SM, Kim HS. Radiofrequency ablation versus surgical resection of hepatocellular carcinoma: contemporary treatment trends and outcomes from the United States National Cancer Database. Eur Radiol 2019; 29 (05) 2679-2689
- 7 Cucchetti A, Piscaglia F, Cescon M. , et al. Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. J Hepatol 2013; 59 (02) 300-307
- 8 He Q, Jiang JJ, Jiang YX, Wang WT, Yang L. ; Liver Surgery Group. Health-related quality of life comparisons after radical therapy for early-stage hepatocellular carcinoma. Transplant Proc 2018; 50 (05) 1470-1474
- 9 Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005; 25 (02) 181-200
- 10 European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56 (04) 908-943
- 11 Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999; 30 (06) 1434-1440
- 12 Chagas AL, Felga GEG, Diniz MA. , et al; Brazilian HCC Study Group. Hepatocellular carcinoma recurrence after liver transplantation in a Brazilian multicenter study: clinical profile and prognostic factors of survival. Eur J Gastroenterol Hepatol 2019; 31 (09) 1148-1156
- 13 Hsu CY, Huang YH, Chiou YY. , et al. Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria: a propensity score analysis. Liver Transpl 2011; 17 (05) 556-566
- 14 Shen PC, Chang WC, Lo CH. , et al. Comparison of stereotactic body radiation therapy and transarterial chemoembolization for unresectable medium-sized hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2019; 105 (02) 307-318
- 15 Vouche M, Habib A, Ward TJ. , et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology 2014; 60 (01) 192-201
- 16 Ni JY, Sun HL, Chen YT. , et al. Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma. World J Gastroenterol 2014; 20 (46) 17483-17490
- 17 Oken MM, Creech RH, Tormey DC. , et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5 (06) 649-655
- 18 National Comprehensive Cancer Network. Older Adult Oncology (Version 1.2019). Available at: https://www.nccn.org/professionals/physician_gls/pdf/senior.pdf . Accessed September 1, 2019
- 19 Lee SK, Song MJ, Kim SH, Park M. Comparing various scoring system for predicting overall survival according to treatment modalities in hepatocellular carcinoma focused on platelet-albumin-bilirubin (PALBI) and albumin-bilirubin (ALBI) grade: a nationwide cohort study. PLoS One 2019; 14 (05) e0216173
- 20 Liu PH, Hsu CY, Hsia CY. , et al. ALBI and PALBI grade predict survival for HCC across treatment modalities and BCLC stages in the MELD Era. J Gastroenterol Hepatol 2017; 32 (04) 879-886
- 21 Antkowiak M, Gabr A, Das A. , et al. Prognostic role of albumin, bilirubin, and ALBI scores: analysis of 1000 patients with hepatocellular carcinoma undergoing radioembolization. Cancers (Basel) 2019; 11 (06) E879
- 22 Sarkar J, DeLeon T, Wong LL. MELD score and AST-to-platelet ratio index (APRI) predict long-term survival in patients with a small hepatocellular carcinoma following non-transplant therapies: a pilot study. Hepatoma Res 2017; 3: 79-85
- 23 Cho JY, Choi MS, Lee GS. , et al. Clinical significance and predictive factors of early massive recurrence after radiofrequency ablation in patients with a single small hepatocellular carcinoma. Clin Mol Hepatol 2016; 22 (04) 477-486
- 24 Kim CG, Lee HW, Choi HJ. , et al. Development and validation of a prognostic model for patients with hepatocellular carcinoma undergoing radiofrequency ablation. Cancer Med 2019; 8 (11) 5023-5032
- 25 Su XF, Li N, Chen XF, Zhang L, Yan M. Incidence and risk factors for liver abscess after thermal ablation of liver neoplasm. Hepat Mon 2016; 16 (07) e34588
- 26 Odisio BC, Richter M, Aloia TA. , et al. Use of prophylactic antibiotics to prevent abscess formation following hepatic ablation in patients with prior enterobiliary manipulation. J Gastrointest Surg 2016; 20 (08) 1428-1434
- 27 Chau GY, Lui WY, Tsay SH. , et al. Prognostic significance of surgical margin in hepatocellular carcinoma resection: an analysis of 165 Childs' A patients. J Surg Oncol 1997; 66 (02) 122-126
- 28 Yoshida Y, Kanematsu T, Matsumata T, Takenaka K, Sugimachi K. Surgical margin and recurrence after resection of hepatocellular carcinoma in patients with cirrhosis. Further evaluation of limited hepatic resection. Ann Surg 1989; 209 (03) 297-301
- 29 Kim YS, Lee WJ, Rhim H, Lim HK, Choi D, Lee JY. The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (> 2 and < 5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion. AJR Am J Roentgenol 2010; 195 (03) 758-765
- 30 Teng W, Liu KW, Lin CC. , et al. Insufficient ablative margin determined by early computed tomography may predict the recurrence of hepatocellular carcinoma after radiofrequency ablation. Liver Cancer 2015; 4 (01) 26-38
- 31 Kim YS, Rhim H, Cho OK, Koh BH, Kim Y. Intrahepatic recurrence after percutaneous radiofrequency ablation of hepatocellular carcinoma: analysis of the pattern and risk factors. Eur J Radiol 2006; 59 (03) 432-441
- 32 Nakazawa T, Kokubu S, Shibuya A. , et al. Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin. AJR Am J Roentgenol 2007; 188 (02) 480-488
- 33 Okuwaki Y, Nakazawa T, Shibuya A. , et al. Intrahepatic distant recurrence after radiofrequency ablation for a single small hepatocellular carcinoma: risk factors and patterns. J Gastroenterol 2008; 43 (01) 71-78
- 34 Liao M, Zhong X, Zhang J. , et al. Radiofrequency ablation using a 10-mm target margin for small hepatocellular carcinoma in patients with liver cirrhosis: a prospective randomized trial. J Surg Oncol 2017; 115 (08) 971-979
- 35 Ke S, Ding XM, Qian X-J. , et al. Radiofrequency ablation of hepatocellular carcinoma sized > 3 and ≤ 5 cm: is ablative margin of more than 1 cm justified?. World J Gastroenterol 2013; 19 (42) 7389-7398
- 36 Han J, Li ZL, Xing H. , et al. The impact of resection margin and microvascular invasion on long-term prognosis after curative resection of hepatocellular carcinoma: a multi-institutional study. HPB (Oxford) 2019; 21 (08) 962-971
- 37 Cuccurullo V, Di Stasio GD, Mazzarella G, Cascini GL. Microvascular invasion in HCC: the molecular imaging perspective. Contrast Media Mol Imaging 2018; 2018: 9487938
- 38 Wang X, Deng Q, Feng K. , et al. Insufficient radiofrequency ablation promotes hepatocellular carcinoma cell progression via autophagy and the CD133 feedback loop. Oncol Rep 2018; 40 (01) 241-251
- 39 Xu M, Doyle MM, Banan B. , et al. Neoadjuvant locoregional therapy and recurrent hepatocellular carcinoma after liver transplantation. J Am Coll Surg 2017; 225 (01) 28-40
- 40 Zhang R, Ma M, Lin XH. , et al. Extracellular matrix collagen I promotes the tumor progression of residual hepatocellular carcinoma after heat treatment. BMC Cancer 2018; 18 (01) 901
- 41 Yoshida S, Kornek M, Ikenaga N. , et al. Sublethal heat treatment promotes epithelial-mesenchymal transition and enhances the malignant potential of hepatocellular carcinoma. Hepatology 2013; 58 (05) 1667-1680
- 42 Tan L, Chen S, Wei G. , et al. Sublethal heat treatment of hepatocellular carcinoma promotes intrahepatic metastasis and stemness in a VEGFR1-dependent manner. Cancer Lett 2019; 460: 29-40
- 43 Agopian VG, Harlander-Locke MP, Ruiz RM. , et al. Impact of pretransplant bridging locoregional therapy for patients with hepatocellular carcinoma within Milan criteria undergoing liver transplantation: analysis of 3601 patients from the US Multicenter HCC Transplant Consortium. Ann Surg 2017; 266 (03) 525-535
- 44 Calderaro J, Ziol M, Paradis V, Zucman-Rossi J. Molecular and histological correlations in liver cancer. J Hepatol 2019; 71 (03) 616-630
- 45 Taouli B, Hoshida Y, Kakite S. , et al. Imaging-based surrogate markers of transcriptome subclasses and signatures in hepatocellular carcinoma: preliminary results. Eur Radiol 2017; 27 (11) 4472-4481
- 46 Yoneda N, Matsui O, Kobayashi S. , et al. Current status of imaging biomarkers predicting the biological nature of hepatocellular carcinoma. Jpn J Radiol 2019; 37 (03) 191-208
- 47 Rhee H, An C, Kim HY, Yoo JE, Park YN, Kim MJ. Hepatocellular carcinoma with irregular rim-like arterial phase hyperenhancement: more aggressive pathologic features. Liver Cancer 2019; 8 (01) 24-40
- 48 Xu P, Zeng M, Liu K, Shan Y, Xu C, Lin J. Microvascular invasion in small hepatocellular carcinoma: is it predictable with preoperative diffusion-weighted imaging?. J Gastroenterol Hepatol 2014; 29 (02) 330-336
- 49 Ryu T, Takami Y, Wada Y. , et al. A clinical scoring system for predicting microvascular invasion in patients with hepatocellular carcinoma within the Milan criteria. J Gastrointest Surg 2019; 23 (04) 779-787
- 50 Navadgi S, Chang CC, Bartlett A, McCall J, Pandanaboyana S. Systematic review and meta-analysis of outcomes after liver resection in patients with hepatocellular carcinoma (HCC) with and without bile duct thrombus. HPB (Oxford) 2016; 18 (04) 312-316
- 51 Shin WY, Suh KS, Lee HW. , et al. Prognostic factors affecting survival after recurrence in adult living donor liver transplantation for hepatocellular carcinoma. Liver Transpl 2010; 16 (05) 678-684
- 52 Cha C, Fong Y, Jarnagin WR, Blumgart LH, DeMatteo RP. Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg 2003; 197 (05) 753-758 3
- 53 Kim JK, Kim HD, Jun MJ. , et al. Tumor volume doubling time as a dynamic prognostic marker for patients with hepatocellular carcinoma. [Erratum appears in Dig Dis Sci. 2017 Nov;62(11):3259] Dig Dis Sci 2017; 62 (10) 2923-2931
- 54 Min JH, Kim YK, Lim S, Jeong WK, Choi D, Lee WJ. Prediction of microvascular invasion of hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging: Impact of intra-tumoral fat detected on chemical-shift images. Eur J Radiol 2015; 84 (06) 1036-1043
- 55 Ma X, Wei J, Gu D. , et al. Preoperative radiomics nomogram for microvascular invasion prediction in hepatocellular carcinoma using contrast-enhanced CT. Eur Radiol 2019; 29 (07) 3595-3605
- 56 Ahn SJ, Kim JH, Park SJ, Kim ST, Han JK. Hepatocellular carcinoma: preoperative gadoxetic acid-enhanced MR imaging can predict early recurrence after curative resection using image features and texture analysis. Abdom Radiol (NY) 2019; 44 (02) 539-548
- 57 Lok AS, Sterling RK, Everhart JE. , et al; HALT-C Trial Group. Des-γ-carboxy prothrombin and α-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010; 138 (02) 493-502
- 58 Paul SB, Gulati MS, Sreenivas V. , et al. Evaluating patients with cirrhosis for hepatocellular carcinoma: value of clinical symptomatology, imaging and alpha-fetoprotein. Oncology 2007; 72 (Suppl. 01) 117-123
- 59 Gurakar A, Ma M, Garonzik-Wang J. , et al. Clinicopathological distinction of low-AFP-secreting vs. high-AFP-secreting hepatocellular carcinomas. Ann Hepatol 2018; 17 (06) 1052-1066
- 60 Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl 2014; 20 (08) 945-951
- 61 Li R, Yang D, Tang CL. , et al. Combined hepatocellular carcinoma and cholangiocarcinoma (biphenotypic) tumors: clinical characteristics, imaging features of contrast-enhanced ultrasound and computed tomography. BMC Cancer 2016; 16: 158
- 62 Lee JH, Chung GE, Yu SJ. , et al. Long-term prognosis of combined hepatocellular and cholangiocarcinoma after curative resection comparison with hepatocellular carcinoma and cholangiocarcinoma. J Clin Gastroenterol 2011; 45 (01) 69-75
- 63 Lee CH, Hsieh SY, Chang CJ, Lin YJ. Comparison of clinical characteristics of combined hepatocellular-cholangiocarcinoma and other primary liver cancers. J Gastroenterol Hepatol 2013; 28 (01) 122-127
- 64 Chen K, Zhan MX, Hu BS. , et al. Combination of the neutrophil to lymphocyte ratio and the platelet to lymphocyte ratio as a useful predictor for recurrence following radiofrequency ablation of hepatocellular carcinoma. Oncol Lett 2018; 15 (01) 315-323
- 65 Lee S, Rhim H, Kim YS, Kang TW, Song KD. Post-ablation des-gamma-carboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma. Liver Int 2016; 36 (04) 580-587
- 66 Xia F, Lai ECH, Lau WY. , et al. High serum hyaluronic acid and HBV viral load are main prognostic factors of local recurrence after complete radiofrequency ablation of hepatitis B-related small hepatocellular carcinoma. Ann Surg Oncol 2012; 19 (04) 1284-1291
- 67 Lou J, Zhang L, Lv S, Zhang C, Jiang S. Biomarkers for hepatocellular carcinoma. Biomarkers in Cancer 2017; 9: 1-9
- 68 Berretta M, Cavaliere C, Alessandrini L. , et al. Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications. Oncotarget 2017; 8 (08) 14192-14220
- 69 Lu DSK, Yu NC, Raman SS. , et al. Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. Radiology 2005; 234 (03) 954-960
- 70 Mazzaferro V, Battiston C, Perrone S. , et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg 2004; 240 (05) 900-909
- 71 Facciorusso A, Di Maso M, Muscatiello N. Microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma: a systematic review and meta-analysis. Int J Hyperthermia 2016; 32 (03) 339-344
- 72 Kamal A, Elmoety AAA, Rostom YAM, Shater MS, Lashen SA. Percutaneous radiofrequency versus microwave ablation for management of hepatocellular carcinoma: a randomized controlled trial. J Gastrointest Oncol 2019; 10 (03) 562-571
- 73 Weber SM, Lee Jr FT, Warner TF, Chosy SG, Mahvi DM. Hepatic cryoablation: US monitoring of extent of necrosis in normal pig liver. Radiology 1998; 207 (01) 73-77
- 74 Wang C, Wang H, Yang W. , et al. Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma. Hepatology 2015; 61 (05) 1579-1590
- 75 Rong G, Bai W, Dong Z. , et al. Long-term outcomes of percutaneous cryoablation for patients with hepatocellular carcinoma within Milan criteria. PLoS One 2015; 10 (04) e0123065
- 76 Di Costanzo GG, Tortora R, D'Adamo G. , et al. Radiofrequency ablation versus laser ablation for the treatment of small hepatocellular carcinoma in cirrhosis: a randomized trial. J Gastroenterol Hepatol 2015; 30 (03) 559-565
- 77 Sutter O, Calvo J, N'Kontchou G. , et al. Safety and efficacy of irreversible electroporation for the treatment of hepatocellular carcinoma not amenable to thermal ablation techniques: a retrospective single-center case series. Radiology 2017; 284 (03) 877-886
- 78 Cheng RG, Bhattacharya R, Yeh MM, Padia SA. Irreversible electroporation can effectively ablate hepatocellular carcinoma to complete pathologic necrosis. J Vasc Interv Radiol 2015; 26 (08) 1184-1188
- 79 Luo W, Zhang Y, He G. , et al. Effects of radiofrequency ablation versus other ablating techniques on hepatocellular carcinomas: a systematic review and meta-analysis. World J Surg Oncol 2017; 15 (01) 126
- 80 Facciorusso A, Serviddio G, Muscatiello N. Local ablative treatments for hepatocellular carcinoma: an updated review. World J Gastrointest Pharmacol Ther 2016; 7 (04) 477-489
- 81 Wang S, Zhuang L, Meng Z. Hepatocellular carcinoma more than 3 cm in diameter: a systematic review of transcatheter arterial chemoembolization plus percutaneous ethanol injection versus transcatheter arterial chemoembolization alone. ISRN Gastroenterol 2013; 2013: 526024
- 82 Pompili M, Mirante VG, Rondinara G. , et al. Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: Assessment of efficacy at explant analysis and of safety for tumor recurrence. Liver Transpl 2005; 11 (09) 1117-1126
- 83 Branco F, Brú C, Vilana R, Bianchi L, Alves de Mattos A. Percutaneous ethanol injection before liver transplantation in the hepatocellular carcinoma. Ann Hepatol 2009; 8 (03) 220-227
- 84 Yu SCH, Hui EP, Tang P. , et al. Transarterial ethanol ablation for unresectable hepatocellular carcinoma: analysis of clinical and tumor outcomes. J Vasc Interv Radiol 2016; 27 (05) 639-649
- 85 Yu SCH, Hui JWY, Hui EP. , et al. Unresectable hepatocellular carcinoma: randomized controlled trial of transarterial ethanol ablation versus transcatheter arterial chemoembolization. Radiology 2014; 270 (02) 607-620
- 86 Fu Y, Zhao X, Yun Q. , et al. Transarterial chemoembolization (TACE) plus percutaneous ethanol injection (PEI) for the treatment of unresectable hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Int J Clin Exp Med 2015; 8 (07) 10388-10400
- 87 Huang H, Liang P, Yu XL. , et al. Safety assessment and therapeutic efficacy of percutaneous microwave ablation therapy combined with percutaneous ethanol injection for hepatocellular carcinoma adjacent to the gallbladder. Int J Hyperthermia 2015; 31 (01) 40-47
- 88 Ahmed AF, Samreen N, Grajo JR. , et al. Angiosomal radiopathologic analysis of transarterial radioembolization for the treatment of hepatocellular carcinoma. Abdom Radiol (NY) 2018; 43 (07) 1825-1836
- 89 Lewandowski RJ, Gabr A, Abouchaleh N. , et al. Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma. Radiology 2018; 287 (03) 1050-1058
- 90 Shah JL, Zendejas-Ruiz IR, Thornton LM. , et al. Neoadjuvant transarterial radiation lobectomy for colorectal hepatic metastases: a small cohort analysis on safety, efficacy, and radiopathologic correlation. J Gastrointest Oncol 2017; 8 (03) E43-E51
- 91 Gates VL, Hickey R, Marshall K. , et al. Gastric injury from (90)Y to left hepatic lobe tumors adjacent to the stomach: fact or fiction?. Eur J Nucl Med Mol Imaging 2015; 42 (13) 2038-2044
- 92 Meek J, Fletcher S, Gauss CH, Bezold S, Borja-Cacho D, Meek M. Temporary balloon occlusion for hepatic arterial flow redistribution during yttrium-90 radioembolization. J Vasc Interv Radiol 2019; 30 (08) 1201-1206
- 93 Su TS, Liang P, Lu HZ. , et al. Stereotactic body radiation therapy for small primary or recurrent hepatocellular carcinoma in 132 Chinese patients. J Surg Oncol 2016; 113 (02) 181-187
- 94 Sapisochin G, Barry A, Doherty M. , et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J Hepatol 2017; 67 (01) 92-99
- 95 Uemura T, Kirichenko A, Bunker M, Vincent M, Machado L, Thai N. Stereotactic body radiation therapy: a new strategy for loco-regional treatment for hepatocellular carcinoma while awaiting liver transplantation. World J Surg 2019; 43 (03) 886-893
- 96 Chan ACY, Cheung TT, Fan ST. , et al. Survival analysis of high-intensity focused ultrasound therapy versus radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma. Ann Surg 2013; 257 (04) 686-692
- 97 Cheung TT, Fan ST, Chu FSK. , et al. Survival analysis of high-intensity focused ultrasound ablation in patients with small hepatocellular carcinoma. HPB (Oxford) 2013; 15 (08) 567-573
- 98 Lu DSK, Raman SS, Limanond P. , et al. Influence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors. J Vasc Interv Radiol 2003; 14 (10) 1267-1274
- 99 Mulier S, Ni Y, Jamart J, Ruers T, Marchal G, Michel L. Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg 2005; 242 (02) 158-171
- 100 Kang TW, Lim HK, Lee MW. , et al. Aggressive intrasegmental recurrence of hepatocellular carcinoma after radiofrequency ablation: risk factors and clinical significance. Radiology 2015; 276 (01) 274-285
- 101 Teratani T, Yoshida H, Shiina S. , et al. Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations. Hepatology 2006; 43 (05) 1101-1108
- 102 Kondo Y, Shiina S, Tateishi R. , et al. Intrahepatic bile duct dilatation after percutaneous radiofrequency ablation for hepatocellular carcinoma: impact on patient's prognosis. Liver Int 2011; 31 (02) 197-205
- 103 Li X, Yu J, Liang P. , et al. Ultrasound-guided percutaneous microwave ablation assisted by three-dimensional visualization operative treatment planning system and percutaneous transhepatic cholangial drainage with intraductal chilled saline perfusion for larger hepatic hilum hepatocellular (D ≥ 3 cm): preliminary results. Oncotarget 2017; 8 (45) 79742-79749
- 104 Silk MT, Wimmer T, Lee KS. , et al. Percutaneous ablation of peribiliary tumors with irreversible electroporation. J Vasc Interv Radiol 2014; 25 (01) 112-118
- 105 Dollinger M, Zeman F, Niessen C. , et al. Bile duct injury after irreversible electroporation of hepatic malignancies: evaluation of MR imaging findings and laboratory values. J Vasc Interv Radiol 2016; 27 (01) 96-103
- 106 Bhutiani N, Philips P, Scoggins CR, McMasters KM, Potts MH, Martin RCG. Evaluation of tolerability and efficacy of irreversible electroporation (IRE) in treatment of Child-Pugh B (7/8) hepatocellular carcinoma (HCC). HPB (Oxford) 2016; 18 (07) 593-599
- 107 Littrup PJ, Aoun HD, Adam B, Krycia M, Prus M, Shields A. Percutaneous cryoablation of hepatic tumors: long-term experience of a large U.S. series. Abdom Radiol (NY) 2016; 41 (04) 767-780
- 108 Dou JP, Yu J, Yang XH. , et al. Outcomes of microwave ablation for hepatocellular carcinoma adjacent to large vessels: a propensity score analysis. Oncotarget 2017; 8 (17) 28758-28768
- 109 Lai ZC, Liang JY, Chen LD. , et al. Do hepatocellular carcinomas located in subcapsular space or in proximity to vessels increase the rate of local tumor progression? A meta-analysis. Life Sci 2018; 207: 381-385
- 110 Francica G, Meloni MF, de Sio I. , et al. Radiofrequency and microwave ablation of subcapsular hepatocellular carcinoma accessed by direct puncture: safety and efficacy. Eur J Radiol 2016; 85 (04) 739-743
- 111 Yu J, Liang P, Yu XL, Cheng ZG, Han ZY, Dong BW. Needle track seeding after percutaneous microwave ablation of malignant liver tumors under ultrasound guidance: analysis of 14-year experience with 1462 patients at a single center. Eur J Radiol 2012; 81 (10) 2495-2499
- 112 Llovet JM, Vilana R, Brú C. , et al; Barcelona Clínic Liver Cancer (BCLC) Group. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology 2001; 33 (05) 1124-1129
- 113 Patel PA, Ingram L, Wilson IDC, Breen DJ. No-touch wedge ablation technique of microwave ablation for the treatment of subcapsular tumors in the liver. J Vasc Interv Radiol 2013; 24 (08) 1257-1262
- 114 Cha DI, Kang TW, Song KD. , et al. Radiofrequency ablation for subcardiac hepatocellular carcinoma: therapeutic outcomes and risk factors for technical failure. Eur Radiol 2019; 29 (05) 2706-2715
- 115 Kang TW, Rhim H, Kim EY. , et al. Percutaneous radiofrequency ablation for the hepatocellular carcinoma abutting the diaphragm: assessment of safety and therapeutic efficacy. Korean J Radiol 2009; 10 (01) 34-42
- 116 Calandri M, Mauri G, Yevich S. , et al. Fusion imaging and virtual navigation to guide percutaneous thermal ablation of hepatocellular carcinoma: a review of the literature. Cardiovasc Intervent Radiol 2019; 42 (05) 639-647
- 117 Cha J, Rhim H, Lee JY. , et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma: assessment of safety in patients with ascites. AJR Am J Roentgenol 2009; 193 (05) W424-W429
- 118 Salem R, Padia SA, Lam M. , et al. Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging 2019; 46 (08) 1695-1704
- 119 Hildebrand P, Leibecke T, Kleemann M. , et al. Influence of operator experience in radiofrequency ablation of malignant liver tumours on treatment outcome. Eur J Surg Oncol 2006; 32 (04) 430-434
- 120 Poon RT, Ng KK, Lam CM. , et al. Learning curve for radiofrequency ablation of liver tumors: prospective analysis of initial 100 patients in a tertiary institution. Ann Surg 2004; 239 (04) 441-449
- 121 Jiang JM, Ohri N, Tang J. , et al. Centers with more therapeutic modalities are associated with improved outcomes for patients with hepatocellular carcinoma. J Gastrointest Oncol 2019; 10 (03) 546-553